Human Immunology News Volume 13.11 | June 10 2025

    By
    Jamie Kang
    -
    0
    1







    2025-06-10 | HIN 13.11


    Human Immunology News by STEMCELL Technologies
    Vol. 13.11 – 10 June, 2025
    TOP STORY

    Unlocking Novel T Cell-Based Immunotherapy for Hepatocellular Carcinoma through Neoantigen-Driven T Cell Receptor Isolation

    Investigators evaluated T cell responses in patients with advanced hepatocellular carcinoma by analyzing tumors, liver flushes, and liver-draining lymph nodes, to understand whether reactive T cell populations could be identified despite the immunosuppressive environment.
    [Gut]

    Full ArticlePress Release
    A close up image from a wallchart about Rational Combination of Cancer Therapies with PD1 Axis Blockade with text that says Free Wallchart, Request a Copy
    PUBLICATIONSListed by the impact factor of the journal

    NLRP6 Deficiency Enhances Macrophage-Mediated Phagocytosis via E-Syt1 to Inhibit Hepatocellular Carcinoma Progression

    Scientists investigated the role of macrophage NOD-like receptor family pyrin domain containing 6 (NLRP6) in hepatocellular carcinoma progression and its therapeutic potential.
    [Gut]

    Full Article

    The MURANO Study: Final Analysis and Retreatment/Crossover Substudy Results of VenR for Patients with Relapsed/Refractory CLL

    Fixed-duration venetoclax-rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the Phase III MURANO trial resulted in superior progression-free survival and overall survival vs bendamustine-rituximab.
    [Blood]

    Abstract
    Graphical Abstract

    IL-10 from Tumoral B Cells Modulates the Diffuse Large B Cell Lymphoma Microenvironment and Response to Immunotherapy

    Researchers showed that IL-10–deficient lymphomas acquire a highly immunosuppressed and T cell–exhausted microenvironment with increased angiogenesis that results in a more aggressive phenotype, which is refractory to PD-1 immune checkpoint blockade.
    [Blood]

    Abstract
    Graphical Abstract

    A Phase I/II Trial of WT1-Specific TCR Gene Therapy for Patients with Acute Myeloid Leukemia and Active Disease Post-Allogeneic Hematopoietic Cell Transplantation: Skewing Towards NK-Like Phenotype Impairs T Cell Function and Persistence

    In this Phase I/II clinical trial, scientists evaluated safety, persistence, and efficacy of Epstein-Barr virus- or Cytomegalovirus-specific Tumor Antigen 1-specific T cell receptor in fifteen patients with active acute myeloid leukemia post-hematopoietic cell transplantation.
    [Nature Communications]

    Full Article

    Combined Dendritic Cell and Anti-TIGIT Immunotherapy Potentiates Adaptive NK Cells against HIV-1

    Investigators demonstrated that dendritic cells primed with nanoparticles containing Poly I:C enhances the natural cytotoxic function of natural killer cells from effective responder people with HIV-1.
    [EMBO Molecular Medicine]

    Full ArticleGraphical Abstract

    Multi-Omics Analyses Reveal Interactions between GREM1+ Fibroblasts and SPP1+ Macrophages in Gastric Cancer

    Tumor-specific GREM1+ fibroblasts and SPP1+ macrophages were significantly enriched in gastric cancer tissues and were involved in immunosuppression, inflammation regulation, and tumor progression.
    [NPJ Precision Oncology]

    Full Article

    Aging-Dependent Change in Th17 and Cytokine Response in Multiple Sclerosis

    Investigators examined whether peripheral production of Myelin Basic Protein-driven cytokine responses mediate the aging-associated decline in multiple sclerosis inflammatory disease activity.
    [Journal of Neuroinflammation]

    Full Article

    Circulating T Cell Atlas in Moyamoya Disease: Insights into Immunopathogenesis of Cerebrovascular Disorders

    Researchers highlighted the critical involvement of immune activation and mitochondrial dysfunction in the pathophysiology of moyamoya disease, providing novel insights into disease mechanisms and identifying immunometabolic pathways as potential targets for therapeutic intervention.
    [Journal of Neuroinflammation]

    Full Article
    REVIEWS

    Artemisinins in Autoimmune Diseases: Effects and Mechanisms in Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Scientists examined artemisinin’s application in systemic lupus erthematosus and rheumatoid arthritis, emphasizing its therapeutic potential and mechanism insights.
    [British Journal of Pharmacology]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Apellis and Sobi Announce EMPAVELI® (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase III Study for C3G and Primary IC-MPGN

    Apellis Pharmaceuticals, Inc. presented new data from the open-label period of the Phase III VALIANT study, investigating EMPAVELI® for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
    [Apellis Pharmaceuticals, Inc. (Globe Newswire)]

    Press Release
    FEATURED EVENT

    Targeting the DNA Damage Response for Cancer Therapeutics Conference

    June 29 – July 2, 2025
    Lisbon, Portugal

    > See All Events

    JOB OPPORTUNITIES

    Research Chair – Human Immunology

    McGill University – Montreal, Quebec, Canada

    Postdoctoral Research Fellow – Tissue Injury and Repair

    The University of Edinburgh – Edinburgh, Scotland, United Kingdom

    Postdoctoral Scientist – Cancer Immunology

    King’s College London – London, England, United Kingdom

    Postdoctoral Research – Wound Healing and Regulatory RNA

    Karolinksa Institutet – Solna, Sweden

    Postgraduate Researcher – Infection, Immunity & Inflammation

    University of Glasgow – Glasgow, Scotland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2